Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. - Abstract - Europe PMC
Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers | BMC Cancer | Full Text
![PDF] Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/e43345f4ce8ef2ceb4bef80df5d990afa4a14046/2-Figure1-1.png "PDF] Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. | Semantic Scholar")
PDF] Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. | Semantic Scholar
SUTENT 12.5mg Hard Capsules - Summary of Product Characteristics (SmPC) - (emc)
Sunitinib Sandoz - NPS MedicineWise
Frontiers | Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation
Biomedicines | Free Full-Text | Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma | HTML
Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma | Anticancer Research
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial - The Lancet
Frontiers | Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First- Line Setting
Overall Survival. (A) OS, (B) Kaplan-Meier Curve for OS From First Line... | Download Scientific Diagram
Improved Survival Outcomes in Advanced RCC Seen with First-Line Immunotherapy, But Benefit Yet to Be Determined in Favorable-Risk Disease
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial - The Lancet Oncology
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers | BMC Cancer | Full Text
Sunitinib - Wikipedia
![PDF] Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/e43345f4ce8ef2ceb4bef80df5d990afa4a14046/4-Figure2-1.png "PDF] Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. | Semantic Scholar")
PDF] Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. | Semantic Scholar
Assessment of prognostic factors in previously treated Japanese patients with metastatic renal cell carcinoma who received nivolumab: An observational multi‑institute study
a) Progression-free survival (PFS) in 90 mRCC patients treated with... | Download Scientific Diagram
Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC - Clinical Genitourinary Cancer
